Fekra Therapeutics is a clinical stage biotech company focused on developing novel first-in-class small-molecule cancer therapeutics. Fekra's lead program is FK-01, an oral BMX non-receptor tyrosine kinase inhibitor with proposed indication for metastatic/non-metastatic Castration-Resistant Prostate Cancer (m/non-mCRPC). Why? Well, Hormonal Therapy ( i.e. Androgen Deprivation Therapy, ADT) is still the mainstay treatment option for patients with progressive prostate cancer. Unfortunately, patients eventually develop resistance to these therapies. Interestingly, the target of interest BMX was found to be overexpressed in response to ADT and contributed to such resistance. Fekra with its FK-01 lead program aims to develop a new and novel therapeutic paradigm for patients with such devastating and progressive cancer.
Company Details
- Employees
- 1
- Founded
- -
- Address
- 6 Liberty Sq,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://fekratx.com
- Keywords
- Novel First-In-Class Small Molecule Cancer Therapeutics, Preclinical Development, Clinical Development.
- HQ
- Boston, Massachusetts
Fekra Therapeutics Questions
Fekra Therapeutics's website is http://fekratx.com
Fekra Therapeutics's LinkedIn profile is https://www.linkedin.com/company/fekra-therapeutics
Fekra Therapeutics has
1 employees.
View email and phone details for 1
employees at Fekra Therapeutics.
Fekra Therapeutics's industry is
Biotechnology Research
Fekra Therapeutics's top competitors are
Ten63 Therapeutics,
Eliksa Therapeutics,
Locus Biosciences, Inc.,
Terray Therapeutics,
Realize Therapeutics,
Incyclix Bio,
Stelexis Biosciences, Inc.,
Airway Therapeutics,
Nivien Therapeutics,
Tavros Therapeutics.
Fekra Therapeutics's categories are Biotechnology Research
Fekra Therapeutics's founding year is 2020
